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Background: Carrier screening for cystic fibrosis is not widely available in Australia, partly 
due to concerns regarding its cost-effectiveness. The benefit of information from pregnancy 
to pregnancy has not been widely considered in existing cost-effectiveness analyses. 
 
Methods: A decision tree was constructed estimating costs and outcomes from screening, 
including both initial and subsequent pregnancies. Effectiveness was expressed in terms of 
CF births averted. Costs were collected using a health service perspective. All costs and 
outcomes were discounted at 5% per annum. 
 
Results: Screening reduced the annual incidence of CF births from 34 to 14/100,000 births 
(an aggregate number of CF births of 100.9 and 41.9 respectively). In initial pregnancies, 
costs in the screening arm (A$16.6 Million/100,000 births) exceed those in the non-screening 
arm (A$13.4 Million/100,000 births). The incremental cost per CF birth in initial pregnancies 
is therefore approximately A$150,000. However, this was reversed for subsequent 
pregnancies, in that the pre-collected information reduces the incidence of CF in subsequent 
pregnancies at low additional costs. When aggregated, the results suggest screening is likely 
to be cost-saving. 
 
Conclusions: The introduction of national carrier screening for cystic fibrosis should be 
considered, as it is likely to reduce CF incidence at an acceptable (potentially negative) cost. 
 







Carrier screening for cystic fibrosis (CF) has been possible since the discovery of the cystic 
fibrosis transmembrance conductance regulator (CFTR) gene. 1, 2 Despite this technological 
advance, there have been few population-based carrier screening programs introduced. An 
early pilot program in Edinburgh used a couple screening model and halved the live birth 
incidence of CF.3 Fee for service pre-conception and prenatal screening are widely practiced 
in the United States, but do not receive government subsidy. Recent guidance from the 
American College of Obstetricians and Gynecologists suggested that CF screening continues 
to be offered to women of reproductive age.4 A small fee for service program has been 
operating in Victoria, Australia since 2006 but does not attract government financial support.5  
 
A key factor for policy makers in funding decisions is an understanding of the economic 
implications of screening. In a resource-constrained environment, social decision-making has 
become increasingly reliant on the evaluation of costs and outcomes in parallel, as typified by 
the Pharmaceutical Benefits Advisory Committee’s (PBAC) central role in determining 
public subsidy of new pharmaceuticals in Australia. 
 
There are several cost-effectiveness analyses of CF carrier screening, that have been 
summarised in a  systematic review.6 The review found that these analyses occurred across a 
range of settings and screening strategies (e.g. stepwise, prenatal, pre-conceptional). The 
review also demonstrated heterogeneity in study design, model inputs and outcome 
measurement, making generalisability of results difficult. Based on the findings of this 




baby averted through prenatal screening in a primary care setting ranges from negative (i.e. it 
is cost-saving)7 through to US$386,773.8 At the time of the review, no study explored the 
costs and benefits of CF screening in Australia. However, a subsequent cost-effectiveness 
analysis did investigate prenatal screening in Australia.9  This concluded that prenatal 
screening using a range of different timing strategies was unlikely to be cost-saving. 
 
One important consideration in this study which was not addressed in the studies reported in 
the systematic review6 (and also the more recent Australian study)9 is to evaluate the impact 
of screening on subsequent reproduction decisions. This is important as providing parents 
with information in initial pregnancies impacts on their decisions in any subsequent 
pregnancies. For example, if a couple knows they are both carriers, they may decide to pursue 
in vitro fertilisation (IVF), or use prenatal diagnosis or to abstain from reproduction. It would 
be expected that parents taking up these options would lead to a reduction in the number of 
CF infants, and also the costs of treating CF and associated conditions (although IVF and 
prenatal diagnosis involve other costs). Similarly, identifying parents as non-carriers has 
implications for subsequent pregnancies, not in terms of reducing CF incidence, but in 
eliminating the need for subsequent testing. 
 
The aim of this study is to provide information to decision makers regarding the optimal 
approach to CF screening within a resource-constrained environment. In particular, we aim to 
explore the impact of information retention on the cost-effectiveness of carrier screening. The 
screening options considered in this study are (i) no screening, (ii) optional pre-conceptional 
screening followed by optional prenatal screening for those who do not take up pre-




with carrier screening approaches for CF based on the experience in Victoria that could be 




The economic evaluation consisted of two components. The first component considered the 
costs and outcomes accruing to infants whose parents had no information regarding their 
carrier status from previous pregnancies (i.e. a screening naïve population). This population 
was termed initial pregnancies in this study. The second component of the economic 
evaluation considered the costs and outcomes accruing to any subsequent infants. For these 
infants, parents have prior knowledge regarding their carrier status, and this was reflected in 
the pathways followed by these infants. This population was termed subsequent pregnancies. 
  
Initial Pregnancies  
 
A decision tree was built based on the Victorian pilot program.5 A decision tree is a technique 
commonly used in cost-effectiveness analysis to describe the pathways an individual can 
follow with respect to a condition, and then to ascribe probabilities, costs and outcomes to 
each of the possible pathways (also called branches). Using these estimates of probabilities, 
costs and outcomes, two or more competing strategies (such as screening and not screening) 
can be compared. In this decision tree, both pre-conceptional and prenatal screening were 
offered. The key elements of the tree are reproduced in Figure 1. The decision tree was built 
in TreeAge Pro 2011, a software designed specifically for this type of conceptual problem. 
 





Figure 1 is simplified, as it does not show the pathways occurring following a false negative 
result (or a false positive, but the model assumes 100% specificity). While these are included 
in the model (available on request), existing studies generally assumed high sensitivity, 
meaning that very few couples would populate those branches of the decision tree.  
 
Screening prenatally and pre-conceptionally have a number of similar features. The key 
difference between the arms is that the latter allows for IVF or abstention from reproduction 
in the first instance for couples identified as being carriers. For prenatal screening, these 
options only exist for subsequent pregnancies. 
 
To complete this analysis, we had to make a number of simplifying assumptions. We 
assumed parenting partnerships are stable; carrier status information is remembered for 
subsequent pregnancies; and following a negative test result, couples proceed with pregnancy 
rather than pursuing further testing (e.g. chorionic villus sampling (CVS)). 
 
Model Inputs 
The parameters required to populate the model are presented in Table 2. All costs are in 
Australian 2010 dollars unless stated. 
 
Table 2 here 
 





The international evidence on the cost of screening is variable, providing a broad range of 
values.6 This is partly due to different cost bases in different countries and settings, but also 
reflects the different cost components included in the estimates. Existing Australian evidence 
regarding the marginal cost of screening suggests a figure of $116.77 per test for pre-natal 
screening.9 This consisted of blood collection ($10), DNA extraction ($11.27), screening test 
consumables ($31.95) and screening test labour ($63.77). These figures are based on a 10-
mutation panel as recommended by the Human Genetics Society of Australasia CF carrier 
screening position statement (available at www.hgsa.org.au). These figures are likely to 
represent an overestimate for a national screening program as they are both likely to include 
aspects of fixed costs which could be shared, and would be subject to economies of scale 
under a larger program. Thus, the analysis biases in favour of not screening as economies of 
scale would be likely to reduce the average cost. 
 
Other Medical Costs 
 
The cost of termination was estimated using Australian Diagnosis-Related Group data from 
2008-9. These data provide an estimate of the total cost of managing a specific type of patient 
including a wide range of different types of cost. In this case, we used DRG O05Z, which 
estimates the total cost of a termination to be $1,708. CVS costs are estimated using Medical 
Benefits Schedule Item number 16603 ($115.20). The costs of an IVF cycle were estimated 
to be between $6,000 and $9,000; for the model we assumed a midpoint of $7,500.10 We do 
not know the number of IVF cycles per couple contingent on choosing IVF as a result of CF 
screening results. It is likely to be below the general IVF population as these couples are less 
likely to have fertility barriers; in our analysis, we have conservatively assumed one cycle per 





Lifetime CF management costs were estimated by Van Gool et al.11 In this, the lifetime costs 
of management of a CF patient were estimated using Australian registry data of CF patients 
in 2003-2005. The lifetime cost of managing a CF patient was estimated to be $336,000, 
assuming a 5% discount rate. This includes costs incurred in the inpatient setting (58%) and 
pharmaceuticals (29%), with the remainder consisting of medical services (including 




A screening program has a variety of relevant outcomes, including carrier status detection, 
reassurance to non-carrier parents, identification of fetuses with CF, reassurance of parents 
with a non-CF baby, information to all prospective parents, or something more general such 
as (quality-adjusted) years of life. For this study, the cost per CF birth averted was specified 
as the primary outcome of interest. Using CF births as an outcome measure is limited as it is 
not comparable to outcomes in other areas of medicine (and health more generally). This 
means it is difficult to interpret for a policy maker facing a wide range of possible uses of 
scarce resources. While quality-adjusted life years (QALYs) represent the gold-standard 
outcome measure for economic evaluation, they include some ethically questionable 
assumptions in situations in which termination can occur.6 For example, can we reasonably 
assume that a CF-baby averted will be followed by a healthy infant (either through CVS 
testing of subsequent pregnancies or IVF)? This is clearly contentious and we therefore do 
not follow this approach. 
   





Costs were collected from a healthcare system perspective. Thus, issues such as productivity 
were excluded. With the exception of the costs of treating people with CF, all costs are 
immediate so are not discounted. The lifetime costs of managing patients with CF were 
generated using a 5% discount rate; the reason for doing this is that it is the standard discount 




A univariate sensitivity analysis was conducted, varying each model parameter within a range 
representing plausible high and low values (reported in Table 2). The systematic review of 
Radhakrishnan et al. provides ranges for many of the parameters.6 The discount rate applied 
to the future healthcare costs of treating an individual with CF is not considered in the 
sensitivity analysis. This is because the range of discount rates (i.e. 0-10%) considered by 
Van Gool et al. produce lifetime costs of care similar to those outlined in Table 2 (i.e. 
increasing or decreasing the cost by 50%). The results are presented in a Tornado plot 
identifying the parameters to which the conclusion is most sensitive. The analysis was 
repeated including and excluding the effect of information from initial infants on 




To model subsequent pregnancies, we categorised these into three groups defined by 
common patterns of screening and risk within each group. We constructed three 




any other options available to these parents, such as abstention from reproduction) in 
subsequent pregnancies based on screening results from a previous pregnancy. These sub-
trees consist solely of the probability of a CF infant (which is described below), and the costs 
associated with each group. If parents cannot have a CF infant in subsequent pregnancies 
(because at least one of the parents is a non-carrier), they enter sub-tree A. If both parents 
received a positive test result (in the sense that they are identified as carriers) for the initial 
pregnancy (and hence are carriers as we assumed specificity to be 1), they enter sub-tree B. In 
sub-tree B, couple choose between no further reproduction, becoming pregnant and use 
prenatal diagnosis, or IVF (with pre-implantation genetic diagnosis, (PGD)). It was therefore 
assumed that no parents both identified as carriers would pursue a pregnancy without at least 
prenatal testing of the infant. Also, if parents have a CF child irrespective of the screening 
results from an initial pregnancy, they enter model B. If the female receives a false negative 
(and hence her partner is not invited for screening), the couple may enter sub-tree C in which 
no screening is undertaken in subsequent pregnancies but there remains a chance of a CF 
baby. This occurs if the father is a carrier (a 4% chance in the base case). If the parents are 
not screened, all parents who are both carriers, but did not have a CF baby in the initial 
pregnancy, enter sub-tree C. This allocation of parents to these options is presented in Table 
1. 
 
Table 1 here 
 
Infants in each of the three supplementary decision trees have different probabilities of CF 
than those screened in the initial program (termed initial infants). This is because their 
parents’ carrier status has been identified (or not in the case of sub-tree C). To identify the 




numbers of initial and subsequent infants. Australian Bureau of Statistics data (2068.0 – 2006 
Census tables) were used to identify the mean number of infants per mother contingent on 
having at least one child. Data from the 44-49 year old cohort was used as they are the 
youngest cohort likely to have no additional children. For this cohort, the average mother had 
1.484 subsequent children after their first born. The total number of subsequent children per 
year is then divided between the terminal (right-hand side) nodes in the decision tree, 
assigned to one of the sub-trees A-C, and the number of CF infants and costs associated with 
subsequent pregnancies were estimated. Note that we have assumed that parents with positive 
CF status will decide to have a similar number of children compared to the general 
population. This assumption is to some extent verified by results from the Australian Cystic 
Fibrosis Data Registry (ACFDR) that show that 20% of CF patients have siblings with CF 
(available at http://www.cysticfibrosis.org.au/pdf/Cystic_Fibrosis_in_Australia_2009.pdf). 
Given that parents with positive carrier status have a 1 in 4 chance of having a baby with CF, 
this would suggest that most CF patients have a sibling. The results including subsequent 
pregnancies are considered in univariate sensitivity analysis using the same approach as that 




In the initial child cohort, prenatal screening was estimated to reduce the number of CF births 
by approximately 53%. For subsequent children, 117.0/100,000 couples ended in group B, in 
which any future reproduction was assumed to take place using IVF or PND. This compared 
with 40.0/100,000 in the No Screening group, reflecting the CF births (0.25*carrier rate^2). 
Screening reduced the population in group C from 120.0/100,000 to 43.3/100,000. In this 





If no screening occurs, the number of CF infants in Australia is estimated to be 40.0/100,000 
in initial pregnancies, and 30.0/100,000 in subsequent pregnancies (as one quarter of carrier 
couples will have their carrier status revealed by having a CF baby). Given the relative size of 
the two groups, this equates to 34.0/100,000 in all pregnancies, or 100.9 per year in Australia.  
 
The model predicts that, under the screening program, the number of CF babies in Australia 
is reduced to 14.0 CF infants per 100,000 pregnancies or 41.4 per annum (from 100.9), a 59% 
reduction. The proportion of initial and subsequent children with CF, and the cost of 
screening for and managing CF in both initial and subsequent populations are provided in 
Table 3. 
 
Table 3 here 
 
The incremental cost of screening first children is estimated to be $16.6 Million - $13.4 
Million = $3.2 Million/100,000 (i.e. the cost offset of reduced treatment of CF does not 
outweigh the cost of screening). The incremental cost per CF birth averted in initial 
pregnancies is $150,000. Whether this represents value for money is uncertain as no 
threshold for this outcome measure exists. However, the reduced treatment costs in 
subsequent births are significant, particularly since a large proportion of identified non-
carriers are not screened in subsequent pregnancies. When weighted to reflect the relative 
sizes of the first and subsequent infant populations, the model estimates a net cost saving 







The model was insensitive to the cost of CVS and termination, the infant mortality risk of 
CVS, and the assumptions concerning whether parents abstain, pursue IVF or PND. The 
results for the remaining parameters for the initial infant only are presented graphically in 
Figure 2. 
 
Figure 2 here 
 
If subsequent infants are included in the sensitivity analysis, all scenarios are cost saving with 
the exception of two. First, if the lifetime cost of CF management is reduced by 50% (to 
$168,000), the cost of the screening program per infant across both initial and subsequent 
births is $9.99. The cost per CF birth averted in this case is $49,928.  Second, if the carrier 
rate is reduced to 2% (instead of the baseline rate of 4%), the cost is $23.95, with a cost per 
CF birth averted of $478,946.  
 
Discussion and Conclusions 
 
We have shown that CF carrier screening can reduce CF in Australia. While carrier screening 
results in an incremental increase in cost per CF birth averted for the first pregnancy 
screened, substantial savings in subsequent pregnancies are likely. The sensitivity analysis 
suggests that the base case result is most sensitive to the cost of the test, the probability of 
termination following a positive CVS test, the lifetime cost of CF management and the carrier 
rate. Of these, the cost of the test is the most uncertain parameter. In this study, no reduction 
in cost has been made to reflect economies of scale; doing so would reduce the incremental 




across all pregnancies. When considering initial pregnancies only, the cost of the test would 
have to fall to $80 to make the program cost-saving. 
 
Relative to the work of Maxwell et al.,9 the findings in this study are more suggestive of a 
screening program recouping costs in terms of reduced incidence of CF, and hence reduced 
costs of care. The reason for this divergence is two-fold. Firstly, we have included the impact 
of information on subsequent pregnancy choices. This is important as many parents will 
require no screening for subsequent pregnancies, and those who are carriers may make 
decisions which reduce the overall prevalence of CF births. The second reason is that we 
have employed new data relating to the cost of treating a CF individual.11 In some regards, 
the estimates of Van Gool et al. are likely to underestimate the cost of a CF case as they 
ignore issues surrounding productivity, both of the CF individual and their parent or carer; 
however, since this is only of relevance if a societal perspective is taken. 
 
An associated practical issue which might be considered in future work is whether public 
subsidy of the sequalae of a carrier screening program is appropriate. For example, if a 
couple are identified to be carriers, should society meet the costs of IVF if the couple choose 
to pursue assisted reproduction? This issue is beyond the scope of this work, but is an 
important philosophical and practical issue which may stem from a universal screening 
program. 
 
This work illustrates the difficulties of economic evaluation in this type of intervention. The 
choice of outcome is contentious for two reasons. Firstly, a screening program provides 
information likely to be valued independent of health gain (e.g. through reassurance). Within 




an intervention, thus ignoring these non-health benefits.13 The second reason is that the 
changes in behaviour resulting from screening occur in multiple dimensions. Screening for 
CF reduces CF incidence, but also impacts on the number of terminations and couples 
abstaining from reproduction. Economic evaluation is usually reliant on combining all 
outcomes into a common outcome measurement, (e.g. the QALY). However, estimating 
QALYs based on CF babies averted, or couples abstaining from reproduction is almost 
impossible and would involve a series of unpalatable or unrealistic assumptions.14 
 
In conclusion, when initial and subsequent pregnancies are considered together, carrier 
screening for CF is cost-effective when analysed in the context of the Australian health care 
system. The generalisability of the conclusion to other countries is uncertain, due to different 
practices towards the management of people with CF, or couples planning or going through 
pregnancy. Costs differ between countries, as do conventions regarding discounting of future 
events. However, our model can be easily replicated and adopted by future researchers to 
examine the cost-effectiveness of carrier screening in other settings.  Translating this 
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Figure 2: Univariate sensitivity analysis (initial infant only) 
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Carrier rate (0.06,0.02)
Probability termination if CVS +ve (1,0.3)
Cost of test (-50%,50%)
Lifetime cost of CF (-50%,50%)
Probability CVS if both parents +ve (1,0.75)
Test sensitivity (0.85,1.00)
Probability male tests if female +ve (1,0.84)
Probability female tests (preconceptual) (0.1,1)
Test specificity (1,0.99)
Probability female tests (prenatal) (0.5,1)
Cost/CF birth averted ($'000s)
 
Note that the order of the values of parameters within the brackets indicates the value which gives the lower and upper estimate of cost / CF birth averted 
 
Table 1: Model Memory 
  Male carrier Male not carrier 






















B A A B 
*: Males are not screened following a negative female result 
A: All subsequent babies do not have CF so no further costs are incurred 
B: All subsequent babies are dependent on choice between IVF, becoming pregnant and 
using prenatal screening or abstaining from reproduction 
C: All subsequent babies are not subject to screening, and have a 25% chance of having CF 
(i.e. probability of baby with two carrier parents having CF) 
 
Table 2: Model Parameters and Assumptions for Sensitivity Analysis 
Parameter Value Source Range (for use in sensitivity analysis) 
Carrier Rate 0.04 Massie et al. 2000 ±50% 
Cost of CVS $115.20 MBS item number ±50% 
Cost of lifetime CF treatment $336,000 Van Gool et al. 2010 ±50% 
Cost of testing $116.77 Maxwell et al. 2010 ±50% 
Cost of termination $1,708 AR-DRG ±50% 
Cost of IVF $7,500 Chambers et al. 2008 ±50% 
Probability mortality (CVS) 0.013 Lieu 1994 0.0075-0.013 (Radhakrishnan et al. 2008) 
Probability CVS test if 2+ve 0.9 Radhakrishnan et al. 20081 0.75-1 (Radhakrishnan et al. 2008) 
Probability male tests if female +ve 0.94 Nielsen 2002 0.84-1.00 (assumption) 
Probability female tests (prenatal) 0.80 Nielsen 2002 0.5-1 (Radhakrishnan et al. 2008) 
Probability female tests 
(preconceptional) 
0.20 Assumption 0.1-1 (Radhakrishnan et al. 2008) 
Probability termination if CVS+ve 0.90 Radhakrishnan et al. 20082 0.3-1 (Radhakrishnan et al. 2008) 
Sensitivity CVS 1 Radhakrishnan et al. 2008 Not considered as all existing studies 
Specificity CVS 1 assume 1 
Test Sensitivity 0.9 Radhakrishnan et al. 20083 0.85-1 (Radhakrishnan et al. 2008) 
Test Specificity  1 Radhakrishnan et al. 2008 0.99-1 (Radhakrishnan et al. 2008) 
Prob (IVF) if both +ve 0.2 Assumption 
0-1 (See note 4 below) 
Prob (abstain) if both +ve 0.2 Assumption 
Prob (postnatal diagnosis) if both 
+ve 
0.6 Assumption 
1 Radhakrishnan et al. identified that assumptions of foetal diagnosis following confirmation of carrier status ranged from 75% to 100%. A figure of 90% was selected to 
represent a typical value. 
2 Radhakrishnan et al. identified that assumptions of termination following identification of a CF fetus ranged from 80% to 95%. A figure of 90% was selected to represent a 
typical value. 
3 Radhakrishnan et al. identified that assumptions of test sensitivity in a general population ranged from 85% to 100%. A figure of 90% was selected to represent a typical 
value. 
4 As these probabilities are mutually exhaustive, increasing one probability has to be reflected in a reduction in one or both of the other two. For the sensitivity analysis, this 
study explores the effect of extreme distributions between the three, assuming in turn that all parents enter IVF, that all parents abstain, and that all parents use prenatal 
diagnosis. 
 
Table 3: Estimated reduction in CF under screening programs 








CF infants per 
100,000 births 


















screening cost / 
CF birth averted 




* This is a weighted mean of the initial and subsequent children, allowing for the relative sizes of the two populations 
 
